Carlisle Companies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.12.22	CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr... (PR Newswire)
22.11.22	U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B (PR Newswire)
02.11.22	Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022 (PR Newswire)
01.11.22	CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology (PR Newswire)
27.10.22	Carlisle Companies Inc. Q3 Profit Increases, beats estimates (RTTNews)
26.10.22	Ausblick: Carlisle Companies stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
12.10.22	Erste Schätzungen: Carlisle Companies zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
06.10.22	CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine (PR Newswire)
05.10.22	CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates (PR Newswire)
26.09.22	New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems (PR Newswire)
26.09.22	New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates (PR Newswire)
13.09.22	CSL presents new research and development center in Marburg, Germany (PR Newswire)
08.09.22	CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors (PR Newswire)
31.08.22	Carlisle TyrFil Announces its 2022 Initiative to Support Reforestation in Ontario, Canada, in Concert with American Forests (PR Newswire)
17.08.22	CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE) (PR Newswire)
17.08.22	CSL announces carbon emissions reduction targets (PR Newswire)
10.08.22	CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY (PR Newswire)
04.08.22	CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology (PR Newswire)
28.07.22	Carlisle Companies Inc. Q2 Profit Increases, beats estimates (RTTNews)
26.07.22	Ausblick: Carlisle Companies stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
11.07.22	Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season (PR Newswire)
22.06.22	CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older (PR Newswire)
09.06.22	Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia (PR Newswire)
06.06.22	Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines (PR Newswire)
02.06.22	Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready (PR Newswire)
24.05.22	FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review (PR Newswire)
11.05.22	Walter Charles Named Senior Vice President and General Manager of CSL Plasma (PR Newswire)
28.04.22	Carlisle Companies Inc. Q1 Profit Increases, beats estimates (RTTNews)
28.04.22	CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Diso... (PR Newswire)
27.04.22	Ausblick: Carlisle Companies gewährt Anlegern Blick in die Bücher (finanzen.net)
13.04.22	Erste Schätzungen: Carlisle Companies verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
28.03.22	European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B (PR Newswire)
02.03.22	Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022 (PR Newswire)
25.02.22	Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response (PR Newswire)
22.02.22	CSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. Communities (PR Newswire)
10.02.22	Carlisle Companies Inc. Q4 Profit Increases, beats estimates (RTTNews)
09.02.22	Ausblick: Carlisle Companies stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
07.02.22	Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology (PR Newswire)
04.02.22	Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022 (PR Newswire)
25.01.22	Carlisle Polyurethane Systems Introduces New Intellathane High-Performance Industrial Protective Spray Coatings Line (PR Newswire)
18.01.22	CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD. (PR Newswire)
15.12.21	CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B (PR Newswire)
07.12.21	New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults (PR Newswire)
23.11.21	Seqirus Announces FDA Approval Of Multi-dose Vial Presentation For AUDENZ (RTTNews)
23.11.21	Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine (PR Newswire)
26.10.21	CSL Plasma Opens 300th Plasma Donation Center in United States (PR Newswire)
22.10.21	Carlisle Group Q3 Profit Increases (RTTNews)
19.10.21	Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021 (PR Newswire)
19.10.21	Ausblick: Carlisle Companies legt Zahlen zum jüngsten Quartal vor (finanzen.net)
19.10.21	Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Carlisle Companies Inc.

Aktien Top/Flop

Meistgelesene Nachrichten